Using pharmacovigilance and multi-omic data, a bivariate regression model of lymphocyte cytosolic protein 1 (LCP1) and adenosine diphosphate-dependent glucokinase (ADPGK) was developed to predict immune-mediated reactions in patients treated with ICPI, including nephritis [19]. This evidence concerns the gene LCP1 and nephritis.